Long-term ACE inhibition doubles lifespan of hypertensive rats

Circulation

Volumn 96, Issue 9, 1997, Pages 3164-3172

  Linz, Wolfgang ^a   Jessen, Timm ^a   Becker, Reinhard H A ^a   Schölkens, Bernward A ^a   Wiemer, Gabriele ^a  

^a SANOFI   (France)

Author keywords

Endothelium; Ramipril; Survival

Indexed keywords

ACETYLCHOLINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; RAMIPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART MUSCLE METABOLISM; HYPERTENSION; ISOLATED HEART; LIFESPAN; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; THORACIC AORTA; VASCULAR ENDOTHELIUM;

EID: 0030699961     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.9.3164     Document Type: Article

References (41)

1. Pitt B, Cohn JN, Francis GS, Kostis JB, Packer M, Pfeffer MA, Swedberg K, Yusuf S. The effect of treatment on survival in congestive heart failure. Clin Cardiol. 1992;15:323-329.
2. Richer C, Fornes P, Vacher E, Bruneval P, Giudicelli J-F. Trandolapril's protective effects in stroke-prone spontaneously hypertensive rats persist long after treatment withdrawal. Am J Cardiol. 1994;73:26C-35C.
3. Stier CT Jr, Chander P, Gutstein WH, Levine S, Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens. 1991;4:680-687.
4. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Group. N Engl J Med. 1987;316: 1429-1435.
5. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:658-691.
6. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet. 1993;342:821-828.
7. HOPE Study Investigators. The HOPE (Heart Outcome Prevention Evaluation) study: the design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12:127-137.
8. Harrap SB, Mirakian C, Datodi SR, Lever AF. Blood pressure and lifespan following brief ACE inhibitor treatment in young spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1994;21: 125-127.
9. Lee RMKW, Delaney KH, Lu M. Perindopril treatment prolonged the lifespan of spontaneously hypertensive rats. J Hypertens. 1995; 13:471-476.
10. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156-159.
11. Fleming I, Fisslthaler B, Busse R. Calcium signalling in endothelial cells involves activation of tyrosine kinases and leads to activation of mitogen-activated protein kinases. Circ Res. 1995;76:522-529.
12. Linz W, Schölkens BA, Han Y-F. Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic hearts. J Cardiovasc Pharmacol. 1986;8(suppl 10):S91-S99.
13. Wiemer G, Fink E, Linz W, Hropot M, Schölkens BA, Wohlfart P. Furosemide enhances the release of endothelial kinins, nitric oxide and prostacyclin. J Pharmacol Exp Ther. 1994;271:1611-1615.
14. Lopez-de Leon A, Rojkind M. A simple method for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem. 1985;33:737-743.
15. Schelling P, Fischer H, Ganten D. Angiotensin and cell growth: a link to cardiovascular hypertrophy? J Hypertens. 1991;9:3-15.
16. Schunkert H, Sadoshima J, Cornelius T, Kagaya Y, Weinberg EO, Izumo S, Riegger G, Lorell BH. Angiotensin II-induced growth responses in isolated adult rat hearts: evidence for load-independent induction of cardiac protein synthesis by angiotensin II. Circ Res. 1995;76:489-497.
17. Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990;86:1913-1920.
18. Baker KM, Chemin MI, Wixson SK, Aceto JF. Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. Am J Physiol. 1990;259(pt 2):H324-H332.
19. Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, Lorell BH. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation. 1993;87:1328-1339.
20. Studer R, Reinecke H, Muller B, Holtz J, Just H, Drexler H. Increased angiotensin-I converting enzyme gene expression in the failing human heart: quantification by competitive RNA polymerase chain reaction. J Clin Invest. 1994;94:301-310.
21. Haber HL, Powers ER, Gimple LW, Wu CC, Subbiah K, Johnson WH, Feldman MD. Intracoronary angiotensin-converting enzyme inhibition improves diastolic function in patients with hypertensive left ventricular hypertrophy. Circulation. 1994;89:2616-2625.
22. Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy: in vivo gene transfer of angiotensin converting enzyme. J Clin Invest. 1994;94:978-984.
23. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.
24. Parratt JR, Vegh A, Papp JG. Bradykinin as an endogenous myocardial protective substance with particular reference to ischemic preconditioning: a brief review of the evidence. Can J Physiol Pharmacol. 1995;73:837-842.
25. 2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats. Hypertension. In press.
26. Groves P, Kurz S, Just H, Drexler H. Role of endogenous bradykinin in human coronary vasomotor control. Circulation. 1995; 92:3424-3430.
27. Kichuk MR, Seyedi N, Zhang X, Marboe CC, Michler RE, Addonizio LJ, Kaley G, Nasjletti A, Hintze TH. Regulation of nitric oxide production in human coronary microvessels and the contribution of local kinin formation. Circulation. 1996;94:44-51.
28. Grunfeld S, Hamilton CA, Mesaros S, McClain SW, Dominiczak AF, Bohr DF, Malinski T. Role of superoxide in the depressed nitric oxide production by the endothelium of genetically hypertensive rats. Hypertension. 1995;26(pt 1):854-857.
29. Tschudi MR, Mesaros S, Lüscher TF, Malinski T. Direct in situ measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension. Hypertension. 1996;27:32-35.
30. Clozel M, Kuhn H, Hefti F. Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension. 1990;16:535-540.
31. Novosel D, Lang MG, Noll G, Lüscher TF. Endothelial dysfunction in aorta of the spontaneously hypertensive, stroke-prone rat: effects of therapy with verapamil and trandolapril alone and in combination. J Cardiovasc Pharmacol. 1994;24:979-985.
32. Kahönen M, Makynen H, Wu X, Arvola P, Pörsti I. Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol. 1995;115:859-867.
33. Tschudi MR, Criscione L, Novosel D, Pfeiffer K, Lüscher TF. Antihypertensive therapy augments endothelium-dependent relaxations in coronary arteries of spontaneously hypertensive rats. Circulation. 1994;89:2212-2218.
34. Gohlke P, Lamberty V, Kuwer I, Bartenbach S, Schnell A, Linz W, Schölkens BA, Wiemer G, Unger T. Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3′,5′-monophosphate. Hypertension. 1993;22:682-687.
35. Wiemer G, Pierchala B, Mesaros S, Schölkens BA, Malinski T. Direct measurement of nitric oxide release from cultured endothelial cells stimulated by bradykinin or ramipril. Endothelium. 1996; 4:119-125.
36. Mancini GBJ, Henry GC, Macaya C, O'Neill B, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard CG, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation. 1996;94:258-265.
37. - release in normotensive and hypertensive rats. Hypertension. In press.
38. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74: 1141-1148.
39. Laursen JB, Rajagopalan S, Galis Z, Tarpey M, Freeman BA, Harrison DG. Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. Circulation. 1997;95: 588-593.
40. Ravichandran LV, Johns RA. Up-regulation of endothelial nitric oxide synthase expression by cyclic guanosine 3′,5′-monophosphate. FEBS Lett. 1995;374:295-298.
41. Morawietz H, Rohrbach S, Darmer D, Hakim K, Zerkowski HR, Holtz J. Angiotensin converting enzyme inhibitor treatment upresulates the expression of endothelial nitric oxide in human atrial myocardium. Circulation. 1996;94(suppl I):I-521. Abstract.